Ισραήλ - Αγγλικά - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone - film coated tablets - dydrogesterone 10 mg - dydrogesterone - dydrogesterone - cases where progesterone supplement is needed.

Ισραήλ - Αγγλικά - Ministry of Health

merck serono ltd - follitropin alfa; lutropin alfa - powder and solvent for solution for injection - follitropin alfa 150 iu; lutropin alfa 75 iu - follitropin alfa - follitropin alfa - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh level < 1.2 iu/l.

Ισραήλ - Αγγλικά - Ministry of Health

teva pharmaceutical industries ltd, israel - tamsulosin hydrochloride - modified release capsules - tamsulosin hydrochloride 0.4 mg - tamsulosin - tamsulosin - treatment of functional symptoms of benign prostatic hyperplasia (bph).

Ισραήλ - Αγγλικά - Ministry of Health

vitamed pharmaceutical industries ltd - minocycline as hydrochloride - capsules - minocycline as hydrochloride 50 mg - minocycline - minocycline - antibiotic indicated against infections caused by bacteria sensitive to minocycline, and for the treatment of acne.

Ισραήλ - Αγγλικά - Ministry of Health

teva pharmaceutical industries ltd, israel - sulphamethoxazole; trimethoprim - suspension - sulphamethoxazole 200 mg / 5 ml; trimethoprim 40 mg / 5 ml - sulfamethoxazole and trimethoprim - sulfamethoxazole and trimethoprim - treatment of urinary tract infections due to susceptible strains of the following organisms: - escherichia coli - klebsiella - enterobacter - proteus mirabilis - proteus vulgaris - proteus morganii. treatment of acute otitis media in children due to susceptible strains of haemophilus influenzae or streptococcus pneumoniae. to date there are limited data available as to the safety of repeated use of resprim in infants under 2 years of age. resprim is not indicated for prophylactic or prolonged administration in otitis media at any age. treatment of acute exacerbations of chronic bronchitis due to susceptible strains of haemophilus influenzae or streptococcus pneumoniae. treatment of enteritis caused by susceptible strains of shigella flexneri and shigella sonnei. resprim is also indicated in the treatment of documented pneumocystis carinii pneumonitis.

Ισραήλ - Αγγλικά - Ministry of Health

dexcel ltd, israel - tobramycin - solution for inhalation - tobramycin 300 mg / 5 ml - tobramycin - tobramycin - tobi is indicated for the management of pulmonary pseudomonas aeruginosa infection in cystic fibrosis (cf) patients age 6 years or older.

Ισραήλ - Αγγλικά - Ministry of Health

bristol - myers squibb, israel - entecavir; entecavir - film coated tablets - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease. baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease.

Ισραήλ - Αγγλικά - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera, a combination of two nucleoside analog hiv 1 reverse transcriptase inhibitors (emtricitabine and tenofovir disoproxil fumarate) and one non-nucleoside reverse transcriptase inhibitor (rilpivirine), is indicated for use as a complete regimen for the treatment of hiv-1 infection in adult patients with no antiretroviral treatment history and with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy, and in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see below).the following points should be considered when initiating therapy with eviplera in adult patients with no antiretroviral treatment history: • more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure (hiv-1 rna ≥50 copies/ml) compared to rilpivirine-treated subjects with hiv-1 rna less than or equal to 100,000 copies/ml [see clinical studies (14)]. • regardless of hiv-1 rna level at the start of therapy, more rilpivirine-treated subjects with cd4+ cell count less than 200 cells/mm3 experienced virologic failure compared to rilpivirine-treated subjects with cd4+ cell count greater than or equal to 200 cells/mm3 [see clinical studies (14)]. • the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz [see microbiology (12.4)]• more subjects treated with rilpivirine developed tenofovir and lamivudine/emtricitabine associated resistance compared to efavirenz [see microbiology (12.4)].

Ισραήλ - Αγγλικά - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera, a combination of two nucleoside analog hiv 1 reverse transcriptase inhibitors (emtricitabine and tenofovir disoproxil fumarate) and one non-nucleoside reverse transcriptase inhibitor (rilpivirine), is indicated for use as a complete regimen for the treatment of hiv-1 infection in adult patients with no antiretroviral treatment history and with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy, and in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see below).the following points should be considered when initiating therapy with eviplera in adult patients with no antiretroviral treatment history: • more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure (hiv-1 rna ≥50 copies/ml) compared to rilpivirine-treated subjects with hiv-1 rna less than or equal to 100,000 copies/ml [see clinical studies (14)]. • regardless of hiv-1 rna level at the start of therapy, more rilpivirine-treated subjects with cd4+ cell count less than 200 cells/mm3 experienced virologic failure compared to rilpivirine-treated subjects with cd4+ cell count greater than or equal to 200 cells/mm3 [see clinical studies (14)]. • the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz [see microbiology (12.4)]• more subjects treated with rilpivirine developed tenofovir and lamivudine/emtricitabine associated resistance compared to efavirenz [see microbiology (12.4)].

Ισραήλ - Αγγλικά - Ministry of Health

bristol, myers squibb (israel) limited, israel - ipilimumab - concentrate for solution for infusion - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - unresectable or metastatic melanomayervoy (ipilimumab) is indicated for the treatment of adult patients with advanced (unresectable or metastatic) melanoma. yervoy in combination with nivolumab is indicated for the treatment of adult and pediatric patients 12 years and older with advanced (unresectable or metastatic) melanoma . advanced renal cell carcinomayervoy, in combination with nivolumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk, advanced renal cell carcinoma (rcc). microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal canceryervoy, in combination with nivolumab, is indicated for the treatment of adult and pediatric patients 12 years of age and older with microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal cancer (crc) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.metastatic non-small cell lung canceryervoy, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumor aberrations.hepatocellular carcinomayervoy, in combination with nivolumab, is indicated for the treatment of adult patients with hepatocellular carcinoma (hcc) child-pugh a who have been previously treated with sorafenib.malignant pleural mesotheliomayervoy, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesotheliomaesophageal canceryervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.